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Do outcomes reported in randomised
controlled trials of joint replacement
surgery fulfil the OMERACT 2.0 Filter? A
review of the 2008 and 2013 literature
Peter D. H. Wall1, Bethan L. Richards2,3, Andrew Sprowson1ˆ, Rachelle Buchbinder4,5 and Jasvinder A. Singh6,7*
Abstract
Background: It is not known, whether outcome reporting in trials of total joint arthroplasty in the recent years is
adequate or not. Our objective was to assess whether outcomes reported in total joint replacement (TJR) trials fulfil
the Outcome Measures in Rheumatology (OMERACT) Filter 2.0.
Methods: We systematically reviewed all TJR trials in adults, published in English in 2008 or 2013. Searches were
conducted in the Cochrane Central Register of Controlled Trials, MEDLINE, and EMBASE. Two authors independently
applied the inclusion criteria for the studies, and any disagreement was resolved with a third review author. All
outcome measures were abstracted using a pre-piloted standardised data extraction form and assessed for whether
they mapped to one of the three OMERACT Filter 2.0 core areas: pathophysiological, life impact, and death.
Results: From 1635 trials identified, we included 70 trials (30 in 2008 and 40 in 2013) meeting the eligibility criteria.
Twenty-two (31%) trials reported the three essential OMERACT core areas. Among the 27 hip replacement surgery
trials and 39 knee replacement surgery trials included, 11 hip (41%) and nine knee (23%) trials reported all three
essential OMERACT core areas. The most common outcome domains/measures were pain (20/27, 74%) and
function (23/27, 85%) in hip trials and pain (26/39, 67%) and function (27/39, 69%) in knee trials. Results were similar
for shoulder and hand joint replacement trials.
Conclusions: We identified significant gaps in the measurement of OMERACT core outcome areas in TJR trials,
despite the majority reporting outcome domains of pain and function. An international consensus of key
stakeholders is needed to develop a core domain set for reporting of TJR trials.
Systematic review registration: PROSPERO CRD42014009216
Keywords: Total joint arthroplasty, Systematic review, OMERACT filter, Core areas, Meta-analysis
Background
For a randomised controlled trial (RCT) to discern the
true effect of an intervention, relevant and robust
outcome measures must be chosen. A standardised set
of outcome measures used across similar types of trials
has the potential to increase their efficiency and value by
enabling comparisons between trials and pooling of data,
thereby providing more precise estimates of the treat-
ment effect.
Twenty years ago the World Health Organization
(WHO) and the International League of Associations for
Rheumatology (ILAR) established a core set of outcomes
for clinical trials in rheumatoid arthritis. This work
originated from the Outcome Measures in Rheumatology
(OMERACT) group that developed a framework and
methodology (i.e. the OMERACT Filter), for the identifi-
cation and validation of core outcome measurement sets
for use in clinical trials, for any health condition [1]. The
* Correspondence: jsingh@uabmc.edu
ˆDeceased
6Birmingham Veterans Affairs Medical Center and University of Alabama at
Birmingham, Faculty Office Tower 805B, 510 20th Street S, Birmingham, AL
35294, USA
7Mayo Clinic School of Medicine, Rochester, MN, USA
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Wall et al. Systematic Reviews  (2017) 6:106 
DOI 10.1186/s13643-017-0498-3
OMERACT group has gone on to develop successful core
outcome measurement sets for other conditions including
ankylosing spondylitis and gout, and the OMERACT
Filter and methodology has been widely adopted inter-
nationally within the rheumatology community [1–3] and
other disciplines [4–6].
Within the discipline of orthopaedic surgery, the de-
velopment of a core outcome measurement set for trials
involving patients with hip fractures is underway [7]. To
our knowledge, there are currently no standardised or
universally accepted core outcome measurement sets for
clinical trials of joint replacement surgery. With over a
million hip and knee joint replacements done each year
in the USA alone [8], and the technology for joint re-
placement surgery evolving rapidly, there is a need for
high-quality randomised controlled trials (RCTs). The
use of standardised measures of outcome assessment in
trials involving joint replacement will facilitate accurate
and effective comparisons of new and existing joint re-
placement implants and techniques, as well as accurate
and effective evaluation of the value of pre- and post-
operative interventions.
In order to improve the reporting of relevant health
outcome domains within joint replacement trials and de-
velop a standard core set, a working group within
OMERACT was established in 2008 and preliminary
work was completed [9–11]. This work demonstrated
the lack of well-validated outcome instruments in knee
and hip clinical trials and identified the need to develop
core outcome domains and a core outcome measure-
ment set with the goal of harmonisation of outcome
measures used in joint replacement clinical trials.
The OMERACT Filter 2.0 defines three “core areas”
that should be measured within a clinical trial of any dis-
ease condition: death, life impact, and pathophysiological
manifestations [1]; it also strongly recommends the
measurement of resource utilisation. The OMERACT
Filter 2.0 provides a roadmap, describing the steps to
achieve a final core measurement set for clinical trials
for a given condition. Firstly, it recommends relevant
stakeholders start by identifying at least one “domain”
within each of the core areas to formulate the “core
domain set;” an additional file shows this in more detail
(see Additional file 1). At least one applicable measure-
ment instrument for each core domain is then identified
to formulate a “core outcome measurement set.” Each
measurement instrument must prove to be truthful
(valid), discriminative, and reliable.
At the OMERACT-12 Meeting (2014), clinical and
methodological experts in epidemiology, psychometrics,
orthopaedics, and rheumatology along with patient part-
ners interested in harmonising outcomes for people
undergoing joint replacement surgery met as a working
group. The ultimate aim of the group is to develop and
reach international consensus on a core outcome meas-
urement set for joint replacement surgery. In prepar-
ation for the meeting, we systematically examined the
outcomes reported in all randomised controlled trials of
joint replacement surgery published in 2008 and 2013.
We found suboptimal reporting of primary outcomes in
TJR trials as well as heterogeneity in the primary out-
comes when reported [12]. In this paper, we report the
extent to which the outcomes reported in the trials fulfil
the OMERACT Filter 2.0 core areas of mortality, life im-
pact, and pathophysiological manifestations, and the
OMERACT Filter 2.0 strongly recommended area, re-
source use.
Methods
We undertook the review in accordance with the Pre-
ferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) guidelines [13, 14]. A
PRISMA checklist is provided as an additional file that
shows this in more detail (see Additional file 2). The
protocol for this review was registered with the Inter-
national Prospective Register of Systematic Reviews
(PROSPERO; Registration number: CRD42014009216).
We included all randomised or quasi-randomised
(where allocation not strictly random) controlled trials
investigating joint replacement surgery (defined as sub-
stitution of any joint surface with a prosthesis) in adult
patients ≥18 years published in either 2008 or 2013. We
chose 2 years only (2008 and 2013) for our study for two
reasons: we anticipated that a 2-year data including a re-
cent year would provide us with a reasonable sample
size for our main study to assess consistency with
OMERACT filter 2.0 [1]; and a secondary objective was
to assess study quality and outcome reporting over time
(2008 to 2013) and due to feasibility issues, since we ex-
pected >100 studies per year to be eligible, limited re-
sources prohibited a review of 6-year trial data (reported
in a separate manuscript ) [12]. We excluded trials in-
vestigating spinal joint replacement surgery and those
trials where the intervention of interest was not part of
the intraoperative insertion of joint replacement pros-
thesis, for example, trials investigating pre-operative
education, peri-operative analgesia, or post-operative
care.
The comparator could include another type of joint
implant, surgical placebo or sham, usual care, physical
therapy, or other active treatments. Trials were included
if at least one outcome had been reported. Only trials
published in English as full articles or available as full
trial report were included.
We searched the Cochrane Central Register of Con-
trolled Trials, MEDLINE, EMBASE, and hand searched
reference lists of relevant articles for randomised or
quasi-randomised controlled trials on 20 March 2014.
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We limited the search to publications in 2008 and 2013,
in order to capture recent trials. The search strategy
used for MEDLINE is provided as an additional file and
shows this in more detail (see Additional file 3).
Two authors (BR and PW) independently assessed the
search results based on the title and abstract, and the full
texts of all potentially eligible studies were then assessed
to identify studies that fulfilled inclusion criteria. Any dis-
agreement in study selection was resolved by consensus or
by discussion with a third review author (RB).
Trial details were extracted for each trial including the
first author, year of publication, and interventions. Add-
itional details including number of participants, year of
recruitment, study duration, and sample size were also
extracted but are reported in a separate manuscript [12].
We extracted all outcome measures using a standar-
dised data extraction form. Outcome measures were then
grouped according to outcome domains and then grouped
according to the three OMERACT core areas, patho-
physiological, life impact, and death or the recommended
area, resource use. Joint-specific multidimensional out-
come measures were broken down into constituent out-
come domains and then grouped according to the four
OMERACT core areas. The data was then aggregated and
reported using simple summary statistics.
Results
There were a total of 1635 potential studies identified
from the initial searches after de-duplication (41
duplicates in 2008 and 60 duplicates in 2013), and 70 tri-
als (30 published in 2008 and 40 published in 2013) met
the eligibility criteria and were included in the review
(Fig. 1). Screening of titles/abstracts was done over
3 weeks, data abstraction over the next 4–6 weeks and
data analyses for the 4 weeks after that. No published
trials of joint replacement involving the foot, ankle, or
elbow were identified. There were 27 trials for hip, 39
trials for knee, three trials for shoulder, and one trial for
replacement surgery of the small joints (Table 1). The
inter-rater agreement was 86% for 2008 and 93% for
2013 initial abstractions. One hundred percent consen-
sus was reached by discussion and with involvement of a
third reviewer. There were 13 joint-specific multidimen-
sional outcome tools reported; all of which measured
outcome domains of both pain and function (Table 2).
Nine (69%) of the joint-specific multidimensional out-
come tools were patient reported.
A mean of six outcome domains were reported per
trial. Twenty-two (31%) trials reported outcome do-
mains/measures in all three of the essential OMERACT
core areas (pathophysiological, life impact, and death),
and 21 (30%) trials reported outcome domains/measures
in the recommended area of resource utilisation.
Hip replacement trial outcome domains
Twenty-seven trials of hip replacement surgery were in-
cluded (10 published in 2008 and 17 published in 2013)
(Table 3). Eighteen unique outcome measures were
Fig. 1 We identified 1635 potential studies from the initial searches after de-duplication (41 duplicates in 2008 and 60 duplicates in 2013 were re-
moved). Seventy trials, 30 published in 2008 and 40 published in 2013 met the eligibility criteria
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Table 1 Studies of hip and knee arthroplasty from 2008 to 2013
Author Joint Comparators
Garcia-Rey 2008 [20] Hip Ultrahigh molecular weight polyethylene liner THR vs. highly cross-linked
polyethylene liner THR
Glyn-Jones 2008a [21] Hip Highly cross-linked polyethylene liner THR vs. ultrahigh molecular weight
polyethylene liner THR
Glyn-Jones 2008b [22] Hip Highly cross-linked polyethylene liner THR vs. ultrahigh molecular weight
polyethylene liner THR
Hamadouche 2008 [23] Hip Polished femoral stem THR vs. matte femoral stem THR
Lachiewicz 2008 [24] Hip Polished femoral stem THR vs. pre-coated femoral stem THR
Macaulay 2008 [25] Hip Hemiarthroplasty vs. THR
Meneghini 2008 [26] Hip Two incision minimally invasive THR vs. mini-posterior approach THR vs.
mini-anterolateral approach THR
Mouzopoulos 2008 [27] Hip Hemiarthroplasty vs. THR vs. internal fixation
Pagnano 2008 [28] Hip Mini-incision THR vs. two incision THR
Pitto 2008 [29] Hip Polyethylene liner THR ceramic liner THR
Barrett 2013 [30] Hip Direct anterior approach THR vs. posterolateral approach THR
Bjorgul 2013 [31] Hip Metal-on-metal bearing THR vs. metal-on-polyethylene bearing THR vs.
ceramic-on-polyethylene bearing THR
Cadossi 2013 [32] Hip Hemiarthroplasty vs. polycarbonateurethane acetabular component THR
Desmarchelier 2013 [33] Hip Metal-on-metal bearing THR vs. ceramic-on-ceramic bearing THR
Greidanus 2013 [34] Hip Minimally invasive anterolateral approach THR vs. minimally invasive direct
lateral approach THR vs. minimally invasive posterolateral approach THR
Hedbeck 2013 [35] Hip Cemented hemiarthroplasty vs. internal fixation
Inngul 2013 [36] Hip Unipolar hemiarthroplasty vs. bipolar hemiarthroplasty
Kim 2013 [37] Hip Alumina-on-alumina ceramic bearing THR vs. alumina on highly cross-linked
polyethylene bearing THR
Landgraeber 2013 [38] Hip Minimally invasive THR vs. conventional THR
Munzinger 2013 [39] Hip Titanium plasma-sprayed cup THR vs. titanium plasma-sprayed cup with
additional hydroxyapatite coating THR
Naudie 2013 [40] Hip Sintered bead porous surface shell THR vs. titanium anatomic porous
surface THR
Penny 2013 [41] Hip Standard THR vs. large head THR vs. resurfacing hip replacement
Smolders 2013 [42] Hip Resurfacing hip replacement vs. THR
Stiehler 2013 [43] Hip Navigated hip resurfacing vs. conventional hip resurfacing
Venditolli 2013 [44] Hip Alumina on alumina vs. metal-on-polyethylene THR
Vidovic 2013 [45] Hip Cemented hemiarthroplasty vs. cementless hemiarthroplasty
Zagra 2013 [46] Hip 28 vs 36 vs. 42 mm bearing THR
Breugem 2008 [47] Knee Fixed bearing TKR vs. mobile bearing TKR
Chaudhary 2008 [48] Knee Posterior cruciate stabilising TKR vs. posterior cruciate-retaining TKR
Dutton 2008 [49] Knee Computer-assisted minimally invasive TKR vs. conventional TKR
Findlay 2008 [50] Knee Cemented TKR vs. uncemented TKR
Hall 2008 [51] Knee Single radius of curvature femoral component TKR vs. multi-radius of
curvature femoral component TKR
Han 2008 [52] Knee Minimally invasive TKR vs. conventional TKR
Hansson 2008 [53] Knee HA-coated TKR vs. Not HA-coated TKR
Harato 2008 [54] Knee Posterior cruciate-retaining TKR vs. Posterior cruciate substituting TKR
Karachalios 2008 [55] Knee Mini-mid vastus approach TKR standard approach TKR
Ladermann 2008 [56] Knee Fixed bearing TKR vs. mobile bearing TKR
Lionberger 2008 [57] Knee Electromagnetic navigation TKR vs. infrared navigation TKR
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identified with a mean of six outcome measures per trial.
Eleven (41%) trials reported an outcome domain/meas-
ure within all three of the essential OMERACT core
areas. The most common outcome domains/measures
reported were pain (20/27, 74%) and function (23/27,
85%).
Seven unique outcome domains/measures mapped to
core area pathophysiological, five mapped to life impact,
five mapped to resource use and one mapped to death.
Core area pathophysiological was represented most
frequently with 86 instances of mapping to this area.
Knee replacement trial outcome domains
Thirty-nine trials of knee replacement surgery were in-
cluded (19 published in 2008 and 20 in 2013) (Table 4).
Twenty-one individual outcome domains/measures were
identified with a mean of six per trial. Nine (23%) trials
reported an outcome domain/measure within all three
Table 1 Studies of hip and knee arthroplasty from 2008 to 2013 (Continued)
Lozano 2008 [58] Knee Extramedullary tibial guide TKR vs. intramedullary tibial guide TKR
Luring 2008 [59] Knee Navigated TKR vs. minimally invasive TKR vs. conventional TKR
Lutzner 2008 [60] Knee Navigated TKR vs. conventional TKR
Nutton 2008 [61] Knee Standard Nexgen TKR vs. high flexion Nexgen TKR
Oberst 2008 [62] Knee Navigated TKR vs. conventional TKR
Smith 2008 [63] Knee Patellar resurfacing TKR vs. no patellar resurfacing TKR
Therbo 2008 [64] Knee HA coated tibial component TKR vs. no HA on tibial component TKR
Wylde 2008 [65] Knee Fixed bearing TKR vs. mobile bearing TKR
Aggarwal 2013 [66] Knee Fixed bearing TKR vs. mobile bearing TKR
Breeman 2013 [67] Knee Mobile bearing TKR vs. fixed bearing TKR
Chareancholvanich 2013 [68] Knee Patient-specific cutting guide TKR vs. conventional instrumentation TKR
Dennis 2013 [69] Knee High flexion TKR vs. standard device TKR
Fischer 2013 [70] Knee High flexion TKR vs. standard device TKR
Hamilton DF 2013a [71] Knee Triathlon TKR vs. Kinemax TKR
Hamilton DF 2013b [72] Knee Triathlon TKR vs. Kinemax TKR
Hamilton WG 2013 [73] Knee Patient-specific instrumentation TKR vs. traditional instrumentation TKR
Jarvis 2013 [74] Knee Standard parapatellar approach TKR vs. mini-parapatellar approach TKR
Joseph 2013 [75] Knee Computer navigation TKR vs. no computer navigation TKR
Jung 2013 [76] Knee Intramedullary alignment TKR vs. extra-medullary alignment TKR
Nieuwenhuijse 2013 [77] Knee LPS-flex mobile TKR vs. LPS-flex-fixed TKR vs. LPS-fixed TKR vs. LPS
mobile TKR
Nishizawa 2013 [78] Knee Cruciate-retaining TKR vs. posterior stabilised TKR
Pandit 2013 [79] Knee Cemented unicompartmental knee replacement vs. cementless
unicompartmental knee replacement
Radetzki 2013 [80] Knee High-flex NexGen LPS flex mobile bearing TKR vs. NexGen LPS TKR
Roh 2013 [81] Knee Patient-specific instruments TKR vs. conventional instruments TKR
Song 2013 [82] Knee Robotic-assisted TKR vs. conventional TKR instruments
Umrani 2013 [83] Knee Patellar eversion TKR vs. no patellar eversion TKR
Wegrzyn 2013 [84] Knee Mini-subvastus approach TKR vs. medial parapatellar approach TKR
Yim 2013 [85] Knee Robot-assisted classical alignment TKR vs. robot-assisted anatomical
alignment TKR
Fialka 2008 [86] Shoulder Has shoulder hemiarthroplasty vs. epoca shoulder hemiarthroplasty
Soliman 2013 [87] Shoulder Hemiarthroplasty and tenodesis of the long head of the biceps vs.
hemiarthroplasty without tenodesis of the long head of the biceps
Lapner 2013 [88] Shoulder Tuberosity osteotomy shoulder replacement vs. subscapularis peel
shoulder replacement
Hansen 2013 [89] Hand Cemented vs. uncemented cups in total trapeziometacarpal
joint prostheses
TKR total knee replacement, THR total hip replacement
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of the essential OMERACT core areas. The most
common outcome domains/measures were pain (26/39,
67%) and function (27/39, 69%). Nine outcome domains
mapped to pathophysiological, five mapped to life im-
pact, six mapped to resource use and one outcome
mapped to death. Core area pathophysiological was rep-
resented most frequently, with 150 instances of mapping
to this area.
Shoulder replacement trial outcome domains
There were three (4%) trials of shoulder replacement sur-
gery; an additional file shows this in more detail (see Add-
itional file 4). Outcome domains/measures of pain, strength,
and activity levels were reported in all three trials. Seven
outcome domains mapped to pathophysiological, three
mapped to life impact, and one outcome domain mapped to
death. Core area pathophysiological was represented most
frequently with 12 instances of mapping to this area.
Hand joint replacement outcome domains
There was one (1%) trial involving replacement of the
small joints of the hand reporting six individual outcome
domains/measures with four mapping to pathophysio-
logical and two to life impact core areas. An additional
file shows this in more detail (see Additional file 4).
Discussion
The purpose of this systematic review was to examine
and highlight inconsistencies in reporting of joint
replacement trials and make recommendations for fu-
ture studies in the area. This systematic review has
highlighted that there are significant gaps in the meas-
urement of OMERACT core outcome areas in joint re-
placement trials. Less than a third (31%) of trials
captured outcome domains/measures within all three es-
sential OMERACT core areas. The majority of joint
replacement trials (but not all) did, however, capture
outcome domains/measures of pain (71%) and function
(77%). This finding is in keeping with the principles and
primary indications for joint replacement surgery, which
are to relieve pain and improve function. All of the
joint-specific multidimensional outcome tools included
in the trials capture both pain and function, which is a
reflection that these measures are well established and
accepted by the orthopaedic community for monitoring
outcomes after joint replacement surgery [15].
All trials captured domains within the core area of
pathophysiological manifestations, with many trials
reporting surrogate outcome domains such as radioster-
iometric analysis (RSA) and plain radiographs to assess
implant loosening. RSA uses x-rays to determine the im-
plant position and is a well-validated tool for measuring
the movement of implants following joint replacement
surgery. RSA requires specialist equipment and training
to use and therefore really only has a role in early/short-
term clinical evaluation of joint replacements. The cor-
relation between movement detected on RSA and longer
term clinically meaningful implant failure is not well
Table 2 Constituent outcomes for multidimensional joint-specific outcome tools
Composite joint-specific outcome tool Proportion of eligible trials
reporting n (%)
Constituent outcomes measured
Merle D’Aubigné and Postel Score (MDPS) 3/27 (11) Pain, function, ROM
Oxford Hip Score (OHS) 2/27 (7) Pain, function
Harris Hip Score (HHS) 15/27 (56) Pain, function, ROM
Hip disability and Osteoarthritis outcomes
score (HOOS)
1/27 (4) Pain, function, hip-related quality of life
Hospital for Special Surgery (HSS) Knee Score 4/39 (10) Pain, function, ROM, knee stability, knee alignment
(not using radiographs)
Knee Society Clinical Rating System (KSS) 16/39 (41) Pain, function, ROM, knee stability, knee alignment
(not using radiographs)
Knee injury and Osteoarthritis Outcome
Score (KOOS)
3/39 (8) Pain, function, knee-related quality of life
Oxford Knee Score (OKS) 6/39 (15) Pain, function
Western Ontario and McMaster Universities
Arthritis Index (WOMAC)
13/66 (20) Pain, function, stiffness
Western Ontario Osteoarthritis of the
Shoulder (WOOS)
1/3 (33) Pain, function, shoulder-related quality of life
American Shoulder and Elbow Surgeons
(ASES)
1/3 (33) Pain, function, activity levels
Constant Score 1/3 (33) Pain, strength, activity levels, ROM
Disabilities of the Arm, Shoulder and Hand
(DASH) Score
1/4 (25) Pain, function, strength, stiffness, hand-related
quality of life
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documented or validated [16]. It is not surprising that
the OMERACT filter 2.0 framework specifies both
pathophysiological manifestations and life impact (such
as pain, function, mobility, quality of life) as two of the
three core areas for any disease construct. In our ex-
ample, filter 2.0 indicates that it is just as important (if
not more) to know the true clinical impact of a differ-
ence in implant positioning between interventions, i.e.
implant failure/revision and pain, function, quality of life
(impact on the patient) as is knowing the exact position-
ing of the implant (e.g. by RSA).
Measurement of mortality is one of the three core areas of
the OMERACT Filter 2.0, but was reported in only 36% of
the trials reviewed. In addition, none of the trials reported
whether or not mortality was considered attributable to the
interventions under study or underlying condition/s. Meas-
urement and reporting of 7-, 30- and 90-day mortality, or
mortality during the trial (3 or 6 or 12 months) could cap-
ture potential intervention-related versus unrelated deaths
and be supplemented with a case by case review to deter-
mine the cause of death. For joint replacement, which is
usually an elective procedure, mortality is rare, but unex-
pected. Therefore, mortality reporting is very important. As
in any clinical trial, study subject mortality is always known
to the investigator and its reporting is quite simple, i.e.
“there were no deaths in this trial,” and or adding a row with
zeros (or the number applicable) to the table showing ad-
verse events of each intervention being compared.
We also found that less than a third (31%) of trials
captured the OMERACT recommended area of resource
utilisation. Without comprehensive data about resource
utilisation, it is difficult to determine the true compara-
tive effectiveness (and cost-effectiveness) of one type of
joint replacement compared to another. A potential rea-
son for this may be a lack of appropriate outcome mea-
sures or a lack of consensus as to which outcome
measure/s to use. Joint replacement is typically an elect-
ive surgery, and therefore, in principle, resource utilisa-
tion is pertinent and appropriate to capture from both
the individual’s and system’s perspective. Outcome tools
would need to be identified which could capture the in-
dividual initial costs of surgery and follow-up hospital
visits but also any additional costs incurred as a result of
further surgery or its complications.
One of the limitations of this review is that we only in-
cluded two snapshots of joint replacement research tri-
als, i.e. trial results published in 2008 and 2013. Our
results may therefore not be truly representative of pe-
riods just before, between and after these dates. On the
other hand, there is no reason to suspect that outcomes/
measures and trial reporting would differ significantly
different in other years.
Successful adoption of the original OMERACT filter
[17] for validation of measures has led to the successful
development and implementation of core domain sets
and core measurement sets for various rheumatic and
non-rheumatic diseases [1, 4–6, 18]. An updated version,
OMERACT filter 2.0, is based on the WHO framework
[1]. OMERACT filter 2.0 provides a practical framework
to develop and validate domains and measures for any
health condition. A pragmatic approach is to use a data-
driven, consensus-based process with multi-stakeholder
involvement to define a minimum measurement set for
all joint replacement trials. In line with the OMERACT
working group’s future agenda for achieving an inter-
national consensus-based core domain set for joint re-
placement trials, and building upon the findings of this
review, we have derived a preliminary core domain set
for joint replacement clinical trials based on the OMER-
ACT filter 2.0 and multi-stakeholder consensus. The
joint replacement clinical trial core domain set includes
six core domains: pain, function, patient satisfaction, re-
vision, adverse events, and death [19].
Conclusions
In conclusion, this systematic review provides insights
into the outcome areas/domains being used and re-
ported in contemporary joint replacement RCTs and
highlights the gaps in this area. The minimum stand-
ard of outcome reporting within joint replacement tri-
als needs improvement. The OMERACT Filter [1]
provides a well-established methodology for improving
this, i.e. providing guidance and methods for develop-
ing a core outcome measurement set. RCTs are ex-
pensive time-consuming studies. As researchers, we
have a duty to patients to extract as much clinically
useful information as possible. The development of a
core outcome measurement set for joint replacement
trials would undoubtedly help to strengthen both the
design and subsequent reporting of results in much
the same way as it has within rheumatology clin-
ical trials, and hopefully advance the field at an accel-
erated pace, by allowing comparisons across trials and
standard meta-analyses.
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